See more : MBL Infrastructures Limited (MBLINFRA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Intelligent Bio Solutions Inc. (INBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intelligent Bio Solutions Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Steadright Critical Minerals Inc. (SCM.CN) Income Statement Analysis – Financial Results
- CDG Co., Ltd. (2487.T) Income Statement Analysis – Financial Results
- MTU Aero Engines AG (MTUAY) Income Statement Analysis – Financial Results
- THK Co., Ltd. (6481.T) Income Statement Analysis – Financial Results
- Medacta Group SA (MEDGF) Income Statement Analysis – Financial Results
Intelligent Bio Solutions Inc. (INBS)
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.69M | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 45.81% | 25.99% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.67M | 507.42K | 3.85M | 4.27M | 588.21K | 3.18M | 2.53M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 139.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K |
| SG&A | 9.26M | 8.03M | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 173.00K |
| Other Expenses | 776.50K | 0.00 | -437.15K | -947.41K | -188.74K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 8.76M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Cost & Expenses | 13.39M | 9.69M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Interest Income | 84.82K | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 | 151.28K |
| Interest Expense | 167.14K | 223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K | 0.00 |
| Depreciation & Amortization | 1.20M | 966.73K | 8.34M | 5.21M | 2.60M | 5.83M | 4.60M | 188.72K |
| EBITDA | -8.81M | -9.47M | 30.83K | -1.82M | -561.19K | -1.50M | -416.92K | -151.28K |
| EBITDA Ratio | -283.14% | -593.55% | 0.00% | -361.23% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | -6.73M | -4.60M | -173.00K |
| Operating Income Ratio | -330.46% | -1,002.11% | 0.00% | -281.42% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 92.24K | 1.93M | 2.90K | -1.71M | -457.75K | -664.84K | -453.31K | -138.67K |
| Income Before Tax | -10.19M | -10.66M | -8.33M | -8.52M | -3.16M | -7.39M | -5.06M | -311.67K |
| Income Before Tax Ratio | -327.50% | -848.50% | 0.00% | -430.15% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 190.70K | -27.93K | 2.50M | 550.26K | -57.69K | -36.39K | -167.01K |
| Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M | -7.34M | -5.02M | -340.01K |
| Net Income Ratio | -326.40% | -845.89% | 0.00% | -355.33% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| EPS | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| EPS Diluted | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| Weighted Avg Shares Out | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
| Weighted Avg Shares Out (Dil) | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis,...
Intelligent Bio Solutions to Participate in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble...
INBS Stock Declines Despite Positive Results of Pharmacokinetic Study
Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused...
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS)...
Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles
New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the...
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing...
GPS Marine Adopts Intelligent Bio Solutions' Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA...
Source: https://incomestatements.info
Category: Stock Reports